PAD - Universidad de Piura (Perú)
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems - Teaching Note
Chess, R; Luthre, JTeaching Note SGSB-E489TN-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €0.00
-
Massachusetts Eye and Ear: Deciding Whether to Join Partners Healthcare
Bundorf, Mary, K; Pathipati, ACase SGSB-P92-EEconomicsThis case follows John Fernandez, CEO of Massachusetts Eye and Ear, as he evaluates whether or not his organization should join Partners HealthCare, the state’s largest healthcare provider. Starting in the mid-2000s, there was a growing trend towards provider consolidation in health care. Many physician practices joined larger groups or hospitals, while independent hospitals integrated into larger health systems. The case explores the causes an...Starting at €8.20
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems
Chess, R; Luthre, JCase SGSB-E489-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €8.20